Sinopharm Group Co. Ltd.
SHTDY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $584,508 | $596,570 | $552,148 | $521,051 |
| % Growth | -2% | 8% | 6% | – |
| Cost of Goods Sold | $540,253 | $548,058 | $504,713 | $477,001 |
| Gross Profit | $44,255 | $48,512 | $47,434 | $44,051 |
| % Margin | 7.6% | 8.1% | 8.6% | 8.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $8,414 | $8,678 | $8,184 | $7,761 |
| SG&A Expenses | $25,572 | $26,150 | $24,903 | $23,199 |
| Sales & Mktg Exp. | $17,159 | $17,472 | $16,720 | $15,438 |
| Other Operating Expenses | $2,495 | $2,153 | $1,926 | $1,140 |
| Operating Expenses | $28,067 | $28,302 | $26,830 | $24,339 |
| Operating Income | $16,188 | $20,209 | $20,604 | $19,712 |
| % Margin | 2.8% | 3.4% | 3.7% | 3.8% |
| Other Income/Exp. Net | -$2,188 | -$697 | -$2,041 | -$2,709 |
| Pre-Tax Income | $14,001 | $19,512 | $18,564 | $17,003 |
| Tax Expense | $3,577 | $4,502 | $4,218 | $3,938 |
| Net Income | $7,050 | $9,054 | $8,526 | $7,759 |
| % Margin | 1.2% | 1.5% | 1.5% | 1.5% |
| EPS | 11.3 | 14.5 | 13.65 | 12.45 |
| % Growth | -22.1% | 6.2% | 9.6% | – |
| EPS Diluted | 11.3 | 14.5 | 13.65 | 12.45 |
| Weighted Avg Shares Out | 624 | 624 | 624 | 622 |
| Weighted Avg Shares Out Dil | 624 | 624 | 624 | 622 |
| Supplemental Information | – | – | – | – |
| Interest Income | $617 | $526 | $543 | $559 |
| Interest Expense | $2,734 | $2,957 | $3,520 | $3,757 |
| Depreciation & Amortization | $2,356 | $4,430 | $4,165 | $3,922 |
| EBITDA | $20,175 | $26,899 | $26,249 | $24,682 |
| % Margin | 3.5% | 4.5% | 4.8% | 4.7% |